Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou
Information source: Chinese University of Hong Kong
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Tuberculosis
Intervention: Directly Observed Therapy (DOTS) plus (Other); Directly Observed Therapy (DOTS) (Other)
Phase: N/A
Status: Recruiting
Sponsored by: Chinese University of Hong Kong Official(s) and/or principal investigator(s): David S Hui, MD, Principal Investigator, Affiliation: Chinese University of Hong Kong
Overall contact: David S Hui, MD, Phone: 852-26323128, Email: dschui@cuhk.edu.hk
Summary
This is a prospective, randomized, parallel, controlled study comparing the efficacy and
outcomes in the retreatment of pulmonary Tuberculosis (TB) in Guangzhou in a group using
pretreatment susceptibility tests in selection of chemotherapy regimens and that in another
group without using pretreatment susceptibility test results. The investigators hypothesize
that selecting drug treatment on the basis of known susceptibility tests would lead to
improved outcome compared with empiric treatment.
Clinical Details
Official title: A Randomized, Parallel, Controlled Study to Evaluate the Role of Directly Observed Therapy Short Course-Plus (DOTS-Plus) Versus DOTS for Retreatment of Relapsed Pulmonary TB in Guangzhou.
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: combined treatment failure/ relapse (unfavourable outcome) among rifampicin resistant group.
Secondary outcome: combined treatment failure/ relapse (unfavourable outcome) among rifampicin resistant group, MDR-TB cases and all retreatment cases;
Detailed description:
The aims are: 1) To evaluate the efficacy and outcomes in the retreatment of pulmonary TB in
Guangzhou by the use of pretreatment susceptibility tests in selection of chemotherapy
regimens & 2) To study the predictive factors of unfavourable outcomes in the retreatment of
pulmonary TB in Guangzhou, where unfavourable outcomes include treatment failures and
relapses.
The patients will be randomized into either a) The DOTS strategy consisting of the following
measures: political commitment, case detection through bacteriologic evaluation,
standardized treatment with supervision and patient support, an effective drug supply
system, and a reporting and recording system that allows assessment of treatment; or b) The
DOTS-Plus strategy includes additional measures including continuous drug resistance
surveillance, culture, drug susceptibility testing for TB patients, and tailoring of
individual drug regimen through the use of first and second-line drugs.
The Primary end point is the 18-month combined treatment failure/ relapse (unfavourable
outcome) among rifampicin resistant group. Secondary endpoints include the 30-month combined
treatment failure/ relapse (unfavourable outcome) among rifampicin resistant group, MDR-TB
cases and all retreatment cases; Sputum smear/conversion rate at 2m, 3m, 8m, 12m, 18m, and
24m; Drug resistance rates to various drugs in particular rifampicin, and rate of MDR-TB.
The predictive factors of unfavourable treatment outcomes (including failure and relapse)
will be analysed.
The management of retreatment cases by DOTS alone is often problematic, especially when
there is resistance to rifampicin, and treatment failure / relapse with further resistances
might result. With implementation of the "DOTS-plus" strategy, HK has achieved a low MDR-TB
prevalence of around 1%. This study will provide important data on the predictors of
treatment failure/ relapse of retreatment cases and whether the DOTS-plus strategy can
effectively reduce the failure/relapse rate and the prevalence rate of MDR-TB in Guangzhou.
The project will provide useful data on the surveillance, epidemiology and public health
control of TB with a regional (cross-border) significance.
Eligibility
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
All consecutive smear positive pulmonary TB patients aged at least 18 years, with past
history of TB treatment, diagnosed with a new episode of active pulmonary TB requiring
treatment will be recruited and randomized into two groups, with Group A with management
based essentially on the DOTS strategy, while Group B based essentially on the DOTS-plus
strategy.
Exclusion Criteria:
- Age < 18 yrs;
- New TB cases (without past history of anti-TB treatment) will be excluded because
they have a much lower risk for MDR-TB than the retreatment cases.
Locations and Contacts
David S Hui, MD, Phone: 852-26323128, Email: dschui@cuhk.edu.hk
Guangzhou Chest Hospital, Guangzhou, Guangdong, China; Recruiting David S Hui, MD, Phone: 852-26323128, Email: dschui@cuhk.edu.hk Chi-Chiu Leung, MBBS, Email: cc_leung@dh.gov.hk Shou-Yong Tan, MD, Principal Investigator
Additional Information
Starting date: March 2009
Last updated: June 12, 2012
|